Oppenheimer Gives a Buy Rating to Soleno Therapeutics (SLNO)


Oppenheimer analyst Leland Gershell assigned a Buy rating to Soleno Therapeutics (SLNO) today and set a price target of $8.00. The company’s shares closed last Wednesday at $1.97.

According to TipRanks.com, Gershell is a 2-star analyst with an average return of 0.4% and a 37.9% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Soleno Therapeutics with a $8.00 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $4.39 and a one-year low of $1.30. Currently, Soleno Therapeutics has an average volume of 615.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Soleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It markets CoSense End-Tidal Carbon Monoxide monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns. The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts